Form 13-F position report

IMMUNITYBIO INC

Reported by ALLIANCEBERNSTEIN L P

IBRX CUSIP 45256X103 Manager CIK 0001109448

Reported 485,080 shares, down 42,380 (8.0%) from the prior quarter.

Reported value 13.2%; share count -8.0% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 485,080 Quarter-end amount reported
Reported value $4,579,155 Fair value at quarter end
Consecutive quarters held 23 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 915000
2022-03-31 1044000
2022-06-30 840000
2022-09-30 1122000
2022-12-31 1144593
2023-03-31 457836
2023-06-30 831248
2023-09-30 499158
2023-12-31 1430349
2024-03-31 960854
2024-06-30 1298950
2024-09-30 764572
2024-12-31 547917
2025-03-31 644230
2025-06-30 928950
2025-09-30 883543
2025-12-31 693970
2026-03-31 744718
2026-06-30 4045618
2026-09-30 4579155

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for IMMUNITYBIO INC held by ALLIANCEBERNSTEIN L P.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 485,080 -42,380 (-8.0%) < 0.01% $4,579,155 2026-11-16
Q2 2026 Added 527,460 +151,340 (40.2%) < 0.01% $4,045,618 2026-08-14
Q1 2026 Added 376,120 +25,630 (7.3%) < 0.01% $744,718 2026-05-15
Q4 2025 Reduced 350,490 -8,674 (-2.4%) < 0.01% $693,970 2026-02-17
Q3 2025 Added 359,164 +7,289 (2.1%) < 0.01% $883,543 2025-11-14
Q2 2025 Added 351,875 +137,845 (64.4%) < 0.01% $928,950 2025-08-14
Q1 2025 Unchanged 214,030 0 (0.0%) < 0.01% $644,230 2025-05-15
Q4 2024 Added 214,030 +8,500 (4.1%) < 0.01% $547,917 2025-02-12
Q3 2024 Unchanged 205,530 0 (0.0%) < 0.01% $764,572 2024-11-14
Q2 2024 Added 205,530 +26,600 (14.9%) < 0.01% $1,298,950 2024-08-14
Q1 2024 Reduced 178,930 -106,000 (-37.2%) < 0.01% $960,854 2024-05-14
Q4 2023 Reduced 284,930 -10,430 (-3.5%) < 0.01% $1,430,349 2024-02-14
Q3 2023 Reduced 295,360 -3,650 (-1.2%) < 0.01% $499,158 2023-11-14
Q2 2023 Added 299,010 +47,452 (18.9%) < 0.01% $831,248 2023-08-15
Q1 2023 Added 251,558 +25,800 (11.4%) < 0.01% $457,836 2023-05-15
Q4 2022 Unchanged 225,758 0 (0.0%) < 0.01% $1,144,593 2023-02-15
Q3 2022 Unchanged 225,758 0 (0.0%) < 0.01% $1,122,000 2022-11-15
Q2 2022 Added 225,758 +39,700 (21.3%) < 0.01% $840,000 2022-08-15
Q1 2022 Added 186,058 +35,500 (23.6%) < 0.01% $1,044,000 2022-05-13
Q4 2021 Added 150,558 +57,058 (61.0%) < 0.01% $915,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

432 managers reported IMMUNITYBIO INC for Q3 2026.

Managers reporting IMMUNITYBIO INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 36,123,813 +2,040,551 < 0.01% $341,008,794 9 qtrs
STATE STREET CORPORATION Reduced 21,095,418 -303,020 < 0.01% $199,140,746 23 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 19,390,126 +1,526,215 < 0.01% $183,042,789 3 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 18,804,937 +3,113,358 < 0.01% $177,518,605 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 10,606,654 +758,758 < 0.01% $100,145,198 23 qtrs
TWO SIGMA INVESTMENTS LP Reduced 5,831,161 -5,265,945 0.04% $55,046,160 8 qtrs
CHARLES SCHWAB INVESTMENT MANAGEMENT INC Added 4,934,258 +2,045,651 < 0.01% $46,579,396 23 qtrs
The Goldman Sachs Group Inc Added 4,129,906 +895,629 < 0.01% $38,986,312 23 qtrs
MILLENNIUM MANAGEMENT LLC Reduced 3,815,755 -1,764,038 0.01% $36,020,727 23 qtrs
UBS Group AG Added 3,775,302 +579,574 < 0.01% $35,638,851 23 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
475,180
Shared
0
None
9,900

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.